Trending in biopharma: From developing vaccines for pandemics, to overcoming omic workflow bottlenecks

Watch exclusive interviews with industry experts on the key to vaccine development success, the role of biomaterials in creating drug models, and more

31 Mar 2022
Blake Forman
Content Creator

Here, we’ve pulled together a playlist of top interviews from The Scientists' Channel, our independent video platform for scientists and clinical experts around the world to share their work. Take a look at the videos below to learn more about the advantages of T-cell vaccines and how to overcome bottlenecks in omics workflows. Plus, discover the role of bioconjugation and protein services in conjugate vaccine development.

Dr. Margaret Liu, CEO of PAX Therapeutics

Developing vaccines for pandemics: Why equity and education are key

Dr. Margaret Liu, CEO of PAX Therapeutics, explains how her early research on vaccine development became critical to the COVID-19 pandemic. Dr. Liu also reveals the advantages of T-cell vaccines, explores some of the key learnings from the pandemic, and highlights the critical role of education in overcoming future health crises.

Watch video

Dr. John Wilson, Founder and CEO of ProtiFi

How to overcome omic workflow bottlenecks

Dr. John Wilson, Founder and CEO of ProtiFi, discusses the importance of reproducibility in omic workflows and explains how ProtiFi has been able to help simplify processes from sample collection and preparation, to process control, chromatography, and data analysis in the early detection of disease.

Watch video

Dr. Andrew Lees, CEO and Scientific Director of Fina Biosciences

The magic behind conjugate vaccine development

Dr. Andrew Lees, CEO and Scientific Director of Fina Biosolutions, explains how Fina Biosolutions has grown to offer a variety of bioconjugation and protein services in its dedication to the provision of affordable conjugate vaccines.

Watch video

Dr. Mohammed Albanna, CEO and Founder of Humabiologics

Advances in biomaterial development

Dr. Mohammad Albanna, CEO and Founder of Humabiologics, discusses his team’s work providing biomaterials for applications such as bioprinting, tissue engineering, and the creation of cancer models for drug screening.

Watch video

Mark Dysinger, Associate Director of Bioanalytical Development at Alexion Pharmaceuticals

Rare disease: How miniaturized immunoassays are advancing therapeutic development

Mark Dysinger, Associate Director, Bioanalytical Development, Alexion Pharmaceuticals, describes how miniaturized immunoassays benefit the accurate analysis of drug-target engagement.

Watch video

Discover more biopharma content on The Scientists' Channel including interviews with speakers who took part in the SelectScience Virtual Biopharmaceutical Summit 2021:

  • Combating cancer: The incubation technology accelerating CAR-T cell therapy development: Dr. Gerhard Bauer, Professor of Hematology and Oncology and Director of the Good Manufacturing Practice (GMP) laboratory at the UC Davis Institute, highlights his current work on the production of CAR-T cells, powerful therapies that use a patient's own immune cells to treat cancer. Watch video >>
  • Developing a whole molecule approach for biopharmaceutical analysis: Dr. John Kellie, Associate Fellow, Bioanalysis, Immunogenicity and Biomarkers, GSK, describes a technique for the quantitation of whole molecule biopharmaceutical candidates using high-resolution mass spectrometry. Watch video >>

Visit The Scientists' Channel to watch new videos and stay up to date on the latest research>>

Links

Tags